Skip to content

This Site is Intended for Healthcare Professionals Only

Search AI Powered

Latest Stories

Boots initiates store closures despite strong quarterly sales

Despite significant sales growth in the quarterly results, high street chemist Boots is moving forward with its plan to close 300 stores in the UK. The move, aimed at improving profit margins amid rising costs and competition, will reduce the chain's portfolio from around 2,200 to just 1,900.

Last month, the U.S.-based Walgreens Boots Alliance, the parent company of Boots, announced upcoming store closures within the next year. However, the company assured that there will be no job losses as all employees will be given the opportunity to be redeployed to nearby shops.


The following sites are confirmed for closure on the specified dates:

  • Heathside Rd, Woking (end of July)
  • UEA campus (end of July)
  • Hamlet Ct Rd, Westcliff-on-Sea (August 1)
  • Windhill Road, Wakefield (October 6)
  • Upper Warrengate, Wakefield (October 7)
  • Glastonbury (October 13)
  • Guildford Road, Woking (end of October)

Boots stores at Salford Shopping Centre in Greater Manchester, Church Street in Malvern, The Port Arcades Shopping Centre in Ellesmere, and King William Street in London have already closed since spring.

Meanwhile, the Pharmacists’ Defence Association has declared its support for members affected by the closure of 300 additional Boots pharmacies. With the announcement of these closures in the coming year, the association believes that not all members will find suitable alternative roles, and some may face the possibility of redundancy.

Boots presently has a workforce of more than 52,000 employees in Britain.

The company achieved robust quarterly results, with retail sales climbing by 13.4 percent and a ninth consecutive quarter of market share growth.

More For You

Locum pharmacists in the UK work in a difficult environment, and many are dissatisfied with their jobs.

Locum pharmacists in the UK work in a difficult environment, and many are dissatisfied with their jobs.

iStock

Locums should stand up for their interests, say 'no' to unfair terms: PDA

The Pharmacists' Defence Association (PDA) has advised locum pharmacists to be vigilant about their interests and negotiate directly with their businesses, avoid working with digital platforms driven by algorithms, and be aware of regressive contract terms.

The not-for-profit organisation issued such an advisory following its survey of 1,300 UK locum pharmacists, which showed that they work in a difficult environment and that most are dissatisfied with their jobs.

Keep ReadingShow less
Wales ranked worst for second-trimester abortion access in the UK

Each year about 175 women travel from Wales to England for care

Wales ranked worst for second-trimester abortion access in the UK

A leading healthcare charity has revealed that Wales is the worst part of the United Kingdom for allowing surgical abortions for women.

Surgical abortion is the process removing pregnancy from the womb by inducing local anaesthesia, conscious sedation or general anaesthesia.

Keep ReadingShow less
The fund offers £150 per eligible child - for up to three children per household.

The fund offers £150 per eligible child - for up to three children per household.

Charity reopens funding to ease back to school financial pressures for community pharmacists

Community pharmacists struggling with the costs of their children going back to school can apply for funding from The Leverhulme Trade Charities Trust (LTCT)

The Trust is providing up to £100,000 of support to those working in a community pharmacy or are a registered pharmacist or pharmacy technician

Keep ReadingShow less
Germany's BioNTech to buy CureVac to boost cancer research

Both biotech companies have been working for years in the area of mRNA vaccines and treatments

Germany's BioNTech to buy CureVac to boost cancer research

Germany's BioNTech is buying domestic rival CureVac for $1.25 billion, bringing together two pharmaceutical firms specialised in mRNA technology with the goal of advancing cancer treatments.

BioNTech, which developed the first coronavirus vaccine to be approved in the West along with US pharmaceutical giant Pfizer, said the acquisition would "bring together complementary capabilities and leverage technologies".

Keep ReadingShow less
Amandeep Doll RPS  New Director of England

Amandeep Doll

RPS announces new director of England

Amandeep Doll has been named as the new director for England at the Royal Pharmaceutical Society (RPS).

The role of Director for England drives professional leadership for the pharmacy profession in England, and leads on national policy development and advocacy across England, in partnership with the English Pharmacy Board.

Keep ReadingShow less